FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Janine Arts

Research Profile

Chemicals & Drugs

Physiology

Procedures

Xenograft Model Antitumor Assays

Anatomy

Living Beings

Disorders

Neoplasms

Concepts & Ideas

Inhibitory Concentration 50

Co-author Network

Publications

TOP 3
Cyrus Chargari; Michel Janicot; Celine Leteur; Bruno Schoentjes; Eric Angevin; Janine Arts; Tarig Bashir; Jean Bourhis; Eric Deutsch
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.
Patrick Angibaud; Kristof Van Emelen; Laurence Decrane; Sven van Brandt; Peter ten Holte; Isabelle Pilatte; Bruno Roux; Virginie Poncelet; David Speybrouck; Laurence Queguiner; Sandrine Gaurrand; Ann Mariën; wim joanna floren; Lut Janssen; Marc Verdonck; Jacky Van Dun; Jacky van Gompel; Ron Gilissen; Claire Mackie; Marc Du Jardin; Jozef Peeters; Marc Noppe; Luc Van Hijfte; Eddy Freyne; Martin Page; Michel Janicot; Janine Arts
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Janine Arts; Peter King; Ann Mariën; wim joanna floren; Ann Beliën; Lut Janssen; Isabelle Pilatte; Bruno Roux; Laurence Decrane; Ron Gilissen; Ian Hickson; Veronique Vreys; Eugene Cox; Kees Bol; Willem Talloen; Ilse Goris; Luc Andries; Marc Du Jardin; Michel Janicot; Martin Page; Kristof Van Emelen; Patrick Angibaud
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Janine Arts (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Cyrus Chargari; Michel Janicot; Celine Leteur; Bruno Schoentjes; Eric Angevin; Janine Arts; Tarig Bashir; Jean Bourhis; Eric Deutsch
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.
Cancer letters 2011;312(2):209-18.
2010: Patrick Angibaud; Kristof Van Emelen; Laurence Decrane; Sven van Brandt; Peter ten Holte; Isabelle Pilatte; Bruno Roux; Virginie Poncelet; David Speybrouck; Laurence Queguiner; Sandrine Gaurrand; Ann Mariën; wim joanna floren; Lut Janssen; Marc Verdonck; Jacky Van Dun; Jacky van Gompel; Ron Gilissen; Claire Mackie; Marc Du Jardin; Jozef Peeters; Marc Noppe; Luc Van Hijfte; Eddy Freyne; Martin Page; Michel Janicot; Janine Arts
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Bioorganic & medicinal chemistry letters 2010;20(1):294-8.
2009: Janine Arts; Peter King; Ann Mariën; wim joanna floren; Ann Beliën; Lut Janssen; Isabelle Pilatte; Bruno Roux; Laurence Decrane; Ron Gilissen; Ian Hickson; Veronique Vreys; Eugene Cox; Kees Bol; Willem Talloen; Ilse Goris; Luc Andries; Marc Du Jardin; Michel Janicot; Martin Page; Kristof Van Emelen; Patrick Angibaud
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6841-51.
2007: Janine Arts; Patrick Angibaud; A Mariën; wim joanna floren; Boudewijn Janssens; P King; Jacky Van Dun; L Janssen; T Geerts; R W Tuman; D L Johnson; Luc Andries; M Jung; Michel Janicot; Kristof Van Emelen
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
British journal of cancer 2007;97(10):1344-53.
2006: A VanderBorght; A Valckx; Jacky Van Dun; T Grand-Perret; Stefanie De Schepper; Jorge Vialard; Michel Janicot; Janine Arts
Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells.
Oncogene 2006;25(50):6672-7.
2006: Ann Beliën; Stefanie De Schepper; wim joanna floren; Boudewijn Janssens; Ann Mariën; Peter King; Jacky Van Dun; Luc Andries; Jan Voeten; Luc Bijnens; Michel Janicot; Janine Arts
Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors.
Molecular cancer therapeutics 2006;5(9):2317-23.
2005: Patrick Angibaud; Janine Arts; Kristof Van Emelen; Virginie Poncelet; Isabelle Pilatte; Bruno Roux; Sven Van Brandt; Marc Verdonck; Hans De Winter; Peter ten Holte; Ann Marien; wim joanna floren; Boudewijn Janssens; Jacky Van Dun; An Aerts; Jacky Van Gompel; Sandrine Gaurrand; Laurence Queguiner; Jean-Michel Argoullon; Luc Van Hijfte; Eddy Freyne; Michel Janicot
Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
European journal of medicinal chemistry 2005;40(6):597-606.
2004: T Grand-Perret; M Cik; Janine Arts; A Vander Borght; M Ercken; A Valckx; A Vermeesen; R Roevens; Michel Janicot
Assay development for high throughput screening of p21(Waf1/Cip1) protein expression in intact cells using fluorometric microvolume assay technology.
Drugs under experimental and clinical research 2004;30(3):89-98.
2003: Janine Arts; Stefanie De Schepper; Kristof Van Emelen
Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.
Current medicinal chemistry 2003;10(22):2343-50.
2003: Stefanie De Schepper; Hélène Bruwiere; Tinne Verhulst; Ulf Steller; Luc Andries; Walter Wouters; Michel Janicot; Janine Arts; Jim Van Heusden
Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.
The Journal of pharmacology and experimental therapeutics 2003;304(2):881-8.